Synaptogenix Net Worth
Synaptogenix Net Worth Breakdown | SNPX |
Synaptogenix Net Worth Analysis
Synaptogenix's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Synaptogenix's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Synaptogenix's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Synaptogenix's net worth analysis. One common approach is to calculate Synaptogenix's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Synaptogenix's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Synaptogenix's net worth. This approach calculates the present value of Synaptogenix's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Synaptogenix's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Synaptogenix's net worth. This involves comparing Synaptogenix's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Synaptogenix's net worth relative to its peers.
To determine if Synaptogenix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Synaptogenix's net worth research are outlined below:
| Synaptogenix generated a negative expected return over the last 90 days | |
| Synaptogenix has high historical volatility and very poor performance | |
| Synaptogenix has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (6.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Synaptogenix currently holds about 28.75 M in cash with (5.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.2. | |
| Synaptogenix has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing |
Synaptogenix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Synaptogenix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Synaptogenix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Synaptogenix's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Synaptogenix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Synaptogenix backward and forwards among themselves. Synaptogenix's institutional investor refers to the entity that pools money to purchase Synaptogenix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hayek Kallen Investment Management | 2023-12-31 | 17.5 K | Elevated Capital Advisors, Llc | 2023-12-31 | 15.9 K | Advisor Group Holdings, Inc. | 2023-12-31 | 3.4 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 2.3 K | Orion Capital Management Llc | 2023-12-31 | 2 K | Ubs Group Ag | 2023-12-31 | 1.8 K | Blackrock Inc | 2023-12-31 | 942 | Acadian Asset Management Llc | 2023-12-31 | 591 | Tower Research Capital Llc | 2023-12-31 | 386 | Renaissance Technologies Corp | 2023-12-31 | 540.9 K | Geode Capital Management, Llc | 2023-12-31 | 154.5 K |
Follow Synaptogenix's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.92 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Synaptogenix's market, we take the total number of its shares issued and multiply it by Synaptogenix's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Synaptogenix's profitablity
Synaptogenix's profitability indicators refer to fundamental financial ratios that showcase Synaptogenix's ability to generate income relative to its revenue or operating costs. If, let's say, Synaptogenix is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Synaptogenix's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Synaptogenix's profitability requires more research than a typical breakdown of Synaptogenix's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.25) | (0.26) |
When accessing Synaptogenix's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Synaptogenix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Synaptogenix's profitability and make more informed investment decisions.
The data published in Synaptogenix's official financial statements usually reflect Synaptogenix's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Synaptogenix. For example, before you start analyzing numbers published by Synaptogenix accountants, it's critical to develop an understanding of what Synaptogenix's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Synaptogenix's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Synaptogenix's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Synaptogenix's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Synaptogenix. Please utilize our Beneish M Score to check the likelihood of Synaptogenix's management manipulating its earnings.
Evaluate Synaptogenix's management efficiency
Synaptogenix has return on total asset (ROA) of (0.1491) % which means that it has lost $0.1491 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.198) %, meaning that it created substantial loss on money invested by shareholders. Synaptogenix's management efficiency ratios could be used to measure how well Synaptogenix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. Non Current Assets Total is likely to rise to about 610 K in 2024, whereas Total Assets are likely to drop slightly above 28.6 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 52.24 | 54.85 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 54.89 | 57.64 | |
| Enterprise Value Over EBITDA | 3.07 | 3.22 | |
| Price Book Value Ratio | 0.13 | 0.12 | |
| Enterprise Value Multiple | 3.07 | 3.22 | |
| Price Fair Value | 0.13 | 0.12 | |
| Enterprise Value | -22.9 M | -24.1 M |
The analysis of Synaptogenix's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Synaptogenix's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Synaptogenix Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Return On Equity (0.20) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Synaptogenix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Synaptogenix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Synaptogenix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bernstein Bruce over two weeks ago Acquisition by Bernstein Bruce of 800 shares of Synaptogenix at 5. subject to Rule 16b-3 | ||
Bernstein Bruce over a year ago Acquisition by Bernstein Bruce of 20000 shares of Synaptogenix subject to Rule 16b-3 |
Synaptogenix Corporate Filings
F4 | 10th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 4th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 1st of April 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
13A | 6th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
Synaptogenix Earnings per Share Projection vs Actual
Be your own money manager
Our tools can tell you how much better you can do entering a position in Synaptogenix without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bollinger Bands Now
Bollinger BandsUse Bollinger Bands indicator to analyze target price for a given investing horizon |
| All Next | Launch Module |
Synaptogenix Corporate Executives
Elected by the shareholders, the Synaptogenix's board of directors comprises two types of representatives: Synaptogenix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Synaptogenix. The board's role is to monitor Synaptogenix's management team and ensure that shareholders' interests are well served. Synaptogenix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Synaptogenix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Weinstein | Executive CFO | Profile |
How to buy Synaptogenix Stock?
The net worth of Synaptogenix is the difference between its total assets and liabilities. Synaptogenix's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Synaptogenix's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Synaptogenix's net worth can be used as a measure of its financial health and stability which can help investors to decide if Synaptogenix is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Synaptogenix stock.Already Invested in Synaptogenix?
The danger of trading Synaptogenix is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Synaptogenix is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Synaptogenix. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Synaptogenix is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Synaptogenix offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Synaptogenix's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Synaptogenix Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Synaptogenix Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Synaptogenix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Synaptogenix Stock please use our How to Invest in Synaptogenix guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Synaptogenix Stock analysis
When running Synaptogenix's price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Synaptogenix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Synaptogenix. If investors know Synaptogenix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Synaptogenix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (29.50) | Return On Assets (0.15) | Return On Equity (0.20) |
The market value of Synaptogenix is measured differently than its book value, which is the value of Synaptogenix that is recorded on the company's balance sheet. Investors also form their own opinion of Synaptogenix's value that differs from its market value or its book value, called intrinsic value, which is Synaptogenix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Synaptogenix's market value can be influenced by many factors that don't directly affect Synaptogenix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Synaptogenix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Synaptogenix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Synaptogenix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.